Hongyan Zang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hongyan Zang has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Gaofeng Ni
Department of Breast Surgery, Yantaishan Hospital Affiliated to Binzhou Medical University, Yantai, China
3 shared publications- Hua Li
Department of General Surgery, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi, China
2 shared publications Wenyang Nie
The First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China
2 shared publicationsXinhan Li
The First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China
2 shared publications- Zhenzhen Zhao
The First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China
2 shared publications - Fu Zhao
The First Clinical Medical College of Shandong University of Traditional Chinese Medicine, Jinan 250014, China
1 shared publication
Latest Publications
- 1 February 2026
- Published by Edizioni Minerva Medica in Minerva Surgery
- Vol. 80 (6)
The study of tumor regression mode, Ki67 expression and neoadjuvant chemotherapy on prognosis of different molecular breast cancer
Article: The study of tumor regression mode, Ki67 expression and neoadjuvant chemotherapy on prognosis of different molecular breast cancer - Minerva Surgery 2023 Dec 21 - Minerva Medica - Journals
- 1 February 2026
- Published by Edizioni Minerva Medica in Minerva Surgery
- Vol. 80 (6)
The study of tumor regression mode, Ki67 expression and neoadjuvant chemotherapy on prognosis of different molecular breast cancer
Article: The study of tumor regression mode, Ki67 expression and neoadjuvant chemotherapy on prognosis of different molecular breast cancer - Minerva Surgery 2023 Dec 21 - Minerva Medica - Journals
- Open Access
- 24 October 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1709624
Correction: Exposing the cellular situation: findings from single-cell RNA sequencing in breast cancer
- 24 October 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1709624
Open AccessCorrection: Exposing the cellular situation: findings from single-cell RNA sequencing in breast cancer
- Open Access
- 6 March 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1539074
Exposing the cellular situation: findings from single cell RNA sequencing in breast cancer
Background: Breast Cancer (BC) ranks among the top three most prevalent cancers globally and stands as the principal contributor to cancer-related fatalities among women. In spite of the substantial occurrence rate of BC, the early stage of this disease is generally regarded as curable. However, intra-tumor heterogeneity presents a formidable obstacle to the success of effective treatment. Method: In this research, single cell RNA sequencing was utilized to dissect the tumor microenvironment within BC. Slingshot, CytoTRACE and Monocle 2 were applied to illustrate the differentiation process of each subpopulation in the pseudotime sequence. To comprehensively comprehend the tumor cells (TCs) in BC, an analysis of upstream transcription factors was carried out via pySCENIC, while downstream pathway enrichment was conducted through KEGG, GO and GSEA. The prognosis model was established based on the bulk data obtained from TCGA and GEO databases. Knock-down experiments were also implemented to explore the function of the transcription factor CEBPD in the TCs. Results: Our in-depth analysis identified eight principal cell types. Notably, TCs were predominantly found within epithelial cells. The classification of TCs further uncovered five unique subpopulations, with one subpopulation characterized by high UGDH expression. This subpopulation was shown to possess distinct metabolic features in metabolism-related investigations. The intricate communication modalities among different cell types were effectively demonstrated by means of CellChat. Additionally, a crucial transcription factor, CEBPD , was identified, which demonstrated a pronounced propensity towards tumors and harbored potential tumor-advancing characteristics. Its role in promoting cancer was subsequently verified through in vitro knock-down experiments. Moreover, a prognostic model was also developed, and a risk score was established based on the genes incorporated in the model. Through comparing the prognoses of different UTRS levels, it was determined that the group with a high UTRS had a less favorable prognosis. Conclusion: These outcomes contributed to the elucidation of the complex interrelationships within the BC tumor microenvironment. By specifically targeting certain subpopulations of TCs, novel treatment strategies could potentially be devised. This study shed light on the direction that future research in BC should take, furnishing valuable information that can be utilized to enhance treatment regimens.
- 6 March 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1539074
Open AccessExposing the cellular situation: findings from single cell RNA sequencing in breast cancer
Background: Breast Cancer (BC) ranks among the top three most prevalent cancers globally and stands as the principal contributor to cancer-related fatalities among women. In spite of the substantial occurrence rate of BC, the early stage of this disease is generally regarded as curable. However, intra-tumor heterogeneity presents a formidable obstacle to the success of effective treatment. Method: In this research, single cell RNA sequencing was utilized to dissect the tumor microenvironment within BC. Slingshot, CytoTRACE and Monocle 2 were applied to illustrate the differentiation process of each subpopulation in the pseudotime sequence. To comprehensively comprehend the tumor cells (TCs) in BC, an analysis of upstream transcription factors was carried out via pySCENIC, while downstream pathway enrichment was conducted through KEGG, GO and GSEA. The prognosis model was established based on the bulk data obtained from TCGA and GEO databases. Knock-down experiments were also implemented to explore the function of the transcription factor CEBPD in the TCs. Results: Our in-depth analysis identified eight principal cell types. Notably, TCs were predominantly found within epithelial cells. The classification of TCs further uncovered five unique subpopulations, with one subpopulation characterized by high UGDH expression. This subpopulation was shown to possess distinct metabolic features in metabolism-related investigations. The intricate communication modalities among different cell types were effectively demonstrated by means of CellChat. Additionally, a crucial transcription factor, CEBPD , was identified, which demonstrated a pronounced propensity towards tumors and harbored potential tumor-advancing characteristics. Its role in promoting cancer was subsequently verified through in vitro knock-down experiments. Moreover, a prognostic model was also developed, and a risk score was established based on the genes incorporated in the model. Through comparing the prognoses of different UTRS levels, it was determined that the group with a high UTRS had a less favorable prognosis. Conclusion: These outcomes contributed to the elucidation of the complex interrelationships within the BC tumor microenvironment. By specifically targeting certain subpopulations of TCs, novel treatment strategies could potentially be devised. This study shed light on the direction that future research in BC should take, furnishing valuable information that can be utilized to enhance treatment regimens.
- Open Access
- 13 January 2025
- Published by Elsevier in Translational Oncology
- Vol. 52, 102280
MAZ-mediated tumor progression and immune evasion in hormone receptor-positive breast cancer: Targeting tumor microenvironment and PCLAF+ subtype-specific therapy
- 13 January 2025
- Published by Elsevier in Translational Oncology
- Vol. 52, 102280
Open AccessMAZ-mediated tumor progression and immune evasion in hormone receptor-positive breast cancer: Targeting tumor microenvironment and PCLAF+ subtype-specific therapy